Join
Live feed
·
PRReleasevia Quantisnow
Polyrizon Ltd. logo

Polyrizon Enrolls First Patient in U.S. Clinical Study of NASARIX (PL-14) Allergy Blocker

ByQuantisnow·Wall Street's wire, on your screen.
PLRZ· Polyrizon Ltd.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track PLRZ (Polyrizon Ltd.) and more on Quantisnow.